• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌监测期间的大小增加:证据综合与剂量反应荟萃分析

Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose-Response Meta-Analysis.

作者信息

Ahmed Mohamed Badie, Naem Emad, Saman Harman, Alsherawi Abeer, Syed Asma, Al-Abdulla Noora, Alkaabi Latifa, Zirie Mahmoud A, Doi Suhail A

机构信息

Department of Population Medicine, College of Medicine, QU Health, Qatar University, Doha, Qatar.

Department of Plastic Surgery, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar.

出版信息

Cancer Rep (Hoboken). 2025 May;8(5):e70183. doi: 10.1002/cnr2.70183.

DOI:10.1002/cnr2.70183
PMID:40344620
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12062514/
Abstract

INTRODUCTION

Differentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active surveillance is now being used to monitor the progression of these lesions and intervene when appropriate. This evidence synthesis aims to assess PTC progression in size over time during active surveillance in terms of PTC tumor size progression to or beyond 3 mm during the surveillance period.

METHODS

A dose-response meta-analysis was conducted using the robust error meta-regression method, using time as the "dose" and cumulative progression (%) was assessed. A comprehensive literature review was done using PubMed/MEDLINE and EMBASE from inception till August 2024.

RESULTS

A total of 21 studies from 7 different countries, including 14 648 participants, were included. Incident progression at 2 years of follow-up was 1%, and this increased linearly to 12% at 20 years of follow-up.

CONCLUSION

It was concluded that progression over the threshold increases linearly over time at approximately less than 1% per year. Therefore, size progression beyond the threshold occurs in a minority and in less than one eighth of subjects by two decades of follow-up.

摘要

引言

分化型甲状腺癌已成为一种常见的恶性肿瘤,尤其是甲状腺乳头状癌(PTC),占病例的90%以上。大多数PTC病变无症状,终生处于亚临床状态,目前正在采用主动监测来监测这些病变的进展并在适当时候进行干预。本证据综合分析旨在根据PTC肿瘤大小在监测期内进展至3毫米或超过3毫米的情况,评估主动监测期间PTC大小随时间的进展。

方法

采用稳健误差元回归方法进行剂量反应荟萃分析,以时间为“剂量”,评估累积进展率(%)。使用PubMed/MEDLINE和EMBASE对从创刊到2024年8月的文献进行了全面综述。

结果

纳入了来自7个不同国家的21项研究,包括14648名参与者。随访2年时的新发进展率为1%,在随访20年时线性增加至12%。

结论

得出的结论是,超过阈值的进展随时间呈线性增加,每年约低于1%。因此,经过二十年的随访,超过阈值的大小进展发生在少数人身上,且不到八分之一的受试者会出现这种情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/81047c2c7248/CNR2-8-e70183-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/fabd40b5e509/CNR2-8-e70183-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/b0176bfade1a/CNR2-8-e70183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/403235c0c42d/CNR2-8-e70183-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/81047c2c7248/CNR2-8-e70183-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/fabd40b5e509/CNR2-8-e70183-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/b0176bfade1a/CNR2-8-e70183-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/403235c0c42d/CNR2-8-e70183-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1b/12062514/81047c2c7248/CNR2-8-e70183-g004.jpg

相似文献

1
Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose-Response Meta-Analysis.甲状腺乳头状癌监测期间的大小增加:证据综合与剂量反应荟萃分析
Cancer Rep (Hoboken). 2025 May;8(5):e70183. doi: 10.1002/cnr2.70183.
2
Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance: A Systematic Review and Meta-analysis.主动监测下低危甲状腺乳头状癌患者年龄与进展的相关性:系统评价和荟萃分析。
JAMA Otolaryngol Head Neck Surg. 2020 Jun 1;146(6):552-560. doi: 10.1001/jamaoto.2020.0368.
3
Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence.低危型甲状腺乳头状癌的主动监测:一种需要更多证据支持的有前途的策略。
J Cancer Res Clin Oncol. 2019 Nov;145(11):2751-2759. doi: 10.1007/s00432-019-03021-y. Epub 2019 Sep 30.
4
Active Surveillance for Small Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis.主动监测小细胞甲状腺癌:系统评价和荟萃分析。
Thyroid. 2019 Oct;29(10):1399-1408. doi: 10.1089/thy.2019.0159. Epub 2019 Sep 27.
5
Nonoperative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.较大恶性和可疑甲状腺结节的非手术、主动监测。
J Clin Endocrinol Metab. 2024 Jul 12;109(8):1996-2002. doi: 10.1210/clinem/dgae082.
6
Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance.谨慎推荐:一项关于在主动监测下甲状腺乳头状癌肿瘤进展情况的荟萃分析。
Am J Otolaryngol. 2023 Nov-Dec;44(6):103994. doi: 10.1016/j.amjoto.2023.103994. Epub 2023 Jul 17.
7
Active Surveillance for T1bN0M0 Papillary Thyroid Carcinoma.T1bN0M0 型甲状腺乳头状癌的主动监测。
Thyroid. 2019 Jan;29(1):59-63. doi: 10.1089/thy.2018.0462. Epub 2019 Jan 8.
8
Tumor Growth Kinetics Based on Initial Tumor Volume Doubling Time in Active Surveillance of Low-Risk Papillary Thyroid Carcinoma.基于低危型甲状腺乳头状癌主动监测中肿瘤倍增时间的肿瘤生长动力学。
Thyroid. 2024 Jul;34(7):846-855. doi: 10.1089/thy.2024.0054.
9
A Protocol for a Pan-Canadian Prospective Observational Study on Active Surveillance or Surgery for Very Low Risk Papillary Thyroid Cancer.加拿大全国范围内主动监测或手术治疗极低危甲状腺乳头状癌的前瞻性观察研究方案。
Front Endocrinol (Lausanne). 2021 Jun 10;12:686996. doi: 10.3389/fendo.2021.686996. eCollection 2021.
10
Applying Criteria of Active Surveillance to Low-Risk Papillary Thyroid Cancer Over a Decade: How Many Surgeries and Complications Can Be Avoided?十年来将主动监测标准应用于低风险甲状腺乳头状癌:可避免多少手术及并发症?
Thyroid. 2017 Apr;27(4):518-523. doi: 10.1089/thy.2016.0568. Epub 2017 Feb 22.

本文引用的文献

1
Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status.根据左旋甲状腺素治疗状态,低危甲状腺微小乳头状癌患者的主动监测结果。
Thyroid. 2023 Oct;33(10):1182-1189. doi: 10.1089/thy.2023.0046. Epub 2023 Jul 5.
2
Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience.主动监测与即刻手术治疗低危型甲状腺微小乳头状癌成人患者的长期疗效:30 年经验
Thyroid. 2023 Jul;33(7):817-825. doi: 10.1089/thy.2023.0076. Epub 2023 May 29.
3
Progression of Low-Risk Papillary Thyroid Microcarcinoma During Active Surveillance: Interim Analysis of a Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma in Korea.
低危型甲状腺微小癌主动监测中的进展:韩国多中心前瞻性甲状腺微小癌主动监测队列研究的中期分析。
Thyroid. 2022 Nov;32(11):1328-1336. doi: 10.1089/thy.2021.0614.
4
Thyroid-Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma in Adults.促甲状腺激素、年龄和肿瘤大小是成人低危甲状腺微小乳头状癌主动监测期间进展的危险因素。
World J Surg. 2023 Feb;47(2):392-401. doi: 10.1007/s00268-022-06770-z. Epub 2022 Oct 2.
5
Bilateral follicular variant of papillary thyroid cancer with different RAS mutations detected with next-generation sequencing: Report of an unusual case and literature review.双侧滤泡状甲状腺癌伴不同 RAS 基因突变的下一代测序检测:不常见病例报告及文献复习。
Diagn Cytopathol. 2022 Oct;50(10):E275-E279. doi: 10.1002/dc.25004. Epub 2022 Jun 18.
6
Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors.靶向髓系来源抑制细胞可逆转免疫抑制,并使 BRAF 突变型甲状腺乳头状癌对 MAPK 抑制剂敏感。
Nat Commun. 2022 Mar 24;13(1):1588. doi: 10.1038/s41467-022-29000-5.
7
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
8
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?评估主动监测期间微小乳头状甲状腺癌的进展:体积增加还是直径增加?
J Clin Med. 2021 Sep 9;10(18):4068. doi: 10.3390/jcm10184068.
9
Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).最小甲状腺外侵犯预测 1 年预后:低-中危甲状腺乳头状癌的纵向多中心研究(ITCO#4)。
Thyroid. 2021 Dec;31(12):1814-1821. doi: 10.1089/thy.2021.0248. Epub 2021 Oct 20.
10
Bias Assessment in Outcomes Research: The Role of Relative Versus Absolute Approaches.结局研究中的偏倚评估:相对与绝对方法的作用。
Value Health. 2021 Aug;24(8):1145-1149. doi: 10.1016/j.jval.2021.02.011. Epub 2021 May 19.